Australia markets closed

Anavex Life Sciences Corp. (AVXL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.08-0.41 (-4.83%)
At close: 04:00PM EST
8.10 +0.02 (+0.25%)
After hours: 07:56PM EST
Full screen
Trade prices are not sourced from all markets
Previous close8.49
Open8.50
Bid0.00 x 900
Ask0.00 x 900
Day's range7.96 - 8.52
52-week range7.13 - 19.83
Volume2,622,080
Avg. volume2,018,041
Market cap629.931M
Beta (5Y monthly)0.71
PE ratio (TTM)N/A
EPS (TTM)-0.58
Earnings date07 Feb 2023 - 13 Feb 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est41.17
  • Zacks

    Anavex's (AVXL) Lead Alzheimer's Drug Meets Study Goal

    Top-line data from a phase IIb/III study shows that Anave's (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function in patients with early Alzheimer's disease.

  • Motley Fool

    Is Anavex Life Sciences a Smart Stock to Buy Now?

    Shares of clinical-stage biotechnology company Anavex Life Sciences (NASDAQ: AVXL) recently shot higher. Investors reacting to great news for its Alzheimer's disease drug candidate, blarcamesine, drove the stock about 40% higher when the market opened on Friday, Dec. 2. Is Anavex Life Sciences a smart stock to buy now, or will the road ahead be a rocky one full of potholes?

  • GlobeNewswire

    Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022

    Webcast and Conference Call To be Held Monday December 5, 2022, 8:30 am ETNEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that management will host